Draft guidance issued for consultation recommends two technologies to help people manage their condition. A digital therapy that could reduce the severity of the symptoms of chronic tic disorders and ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a simple discount patient access scheme for brentuximab vedotin. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Osimertinib with pemetrexed and platinum-based chemotherapy (Tagrisso) is available on the NHS as a possible treatment for advanced non-small-cell lung cancer that has not been treated before. It is ...

The following considerations around implementing the evidence generation process have been identified through working with system partners: ...

Tools to help you put the guidance into practice.

Brentuximab vedotin (Adcetris) with doxorubicin, dacarbazine and vinblastine is available on the NHS. It is a possible treatment for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Osimertinib (Tagrisso, AstraZeneca) with pemetrexed and platinum-based chemotherapy is indicated for 'the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 ...